The startup rewiring how biologic medicine gets made - by turning the egg into a drug factory.
Neion Bio is a New York biotechnology company that genetically engineers chicken eggs into factories for complex biologic drugs. Where the industry builds cathedral-scale plants of stainless-steel tanks, Neion is betting that biology already built a better bioreactor - and it fits in the palm of your hand.
The hardest part of a modern biologic drug is not discovering it. It is making it. Monoclonal antibodies - the workhorse molecules behind many of today's most important therapies - are large, delicate, and heavily sugar-coated proteins that are notoriously expensive to manufacture. The conventional route grows them in mammalian cell cultures inside enormous, capital-intensive facilities that can take years and hundreds of millions of dollars to build.
Neion Bio, founded in 2024 by Demetrios "Dimi" Kellari and Dr. Sam Levin, takes a different route. Its proprietary Raptor platform uses precision genetic engineering to restrict recombinant protein production to the egg itself, harnessing a system that evolution has spent millions of years optimizing to churn out complex proteins.
The company emerged from stealth in March 2026 - not with a slide deck, but with a signed commercial biosimilar partnership already in hand. Three months later it closed an oversubscribed $23 million Series A. For a company built around an idea that sounds, at first, like a joke, the money is following a serious thesis: cost is a design choice, and the bioreactor is due for a rethink.
Figures per company statements and press reports, March-June 2026. Total raised combines a ~$11M seed and a $23M Series A.
Millions of years of evolution have sculpted this system into an extremely prolific producer of complex proteins.
The pitch is simple to say and hard to build: engineer the bird so the drug is made inside the egg, then harvest it. The details are where the science lives.
Precision genetic engineering programs the target protein - such as a monoclonal antibody - into the biology.
Raptor confines recombinant protein production to the egg itself, keeping the system contained and consistent.
The egg's natural machinery makes complex, glycosylated proteins - within days, at low marginal cost.
Proteins are collected and purified for use as biosimilars, medicines, reagents, or animal-health products.
The core genetic-engineering platform that turns eggs into bioreactors for complex glycosylated proteins.
Lower-cost versions of complex biologics, including monoclonal antibodies - the focus of the first pharma deal.
Novel therapeutic proteins developed natively on the egg-based platform.
Research and industrial proteins produced at lower cost with a resilient, localizable supply.
Biologics and proteins for the veterinary and animal-health market.
Co-development and supply deals with upfront payments, milestones, and long-term profit sharing.
Neion's customers are biopharmaceutical and animal-health companies that need to manufacture biologic drugs, biosimilars, and proteins - and would rather not spend years and hundreds of millions building a plant to do it.
As of mid-2026, one commercial partner is disclosed: a major global pharmaceutical company, in a deal covering up to three monoclonal antibody biosimilars. The agreement includes upfront payments, milestone-based compensation, and long-term profit sharing after commercialization.
The dominant way to make biologics is mammalian cell culture in stainless-steel bioreactors, run by large contract manufacturers. It works, but it is expensive, slow to build, and centralized.
Egg-based production is not new - it has made vaccines for a century. Neion's twist is applying frontier genetic engineering to produce modern recombinant biologics in eggs, aiming for a manufacturing base that is cheaper, greener, and can run closer to where medicine is needed.
Cost is a design choice. Neion's wager is that the most basic assumption in biologics - the tank - is the one worth questioning.
Demetrios Kellari trained as an aerospace engineer at MIT and worked at GoogleX and McKinsey before turning to biomanufacturing.
The scientific architect behind the Raptor platform and its approach to producing complex proteins in eggs.
Leads the company's core scientific strategy across genome engineering and biology.
Directs the avian biology at the heart of the platform.
Industry veteran leading Neion's commercial operations and partnerships.
A small, multidisciplinary group spanning engineering, molecular and avian biology, and commercial pharma.
Two rounds in one year, both led by Caffeinated Capital, an early believer in the egg thesis.
| Round | Amount | Date | Lead & notable investors |
|---|---|---|---|
| Seed | ~$11M | Mar 2026 | Caffeinated Capital (lead), Basis Set Ventures, Haystack VC |
| Series A | $23M | Jun 2026 | Caffeinated Capital (lead); new: Digitalis Ventures, Ensemble VC, Trust Ventures; follow-on: Haystack, Basis Set Ventures |
The Series A was reported as oversubscribed. Valuation not disclosed.
Dimi Kellari and Dr. Sam Levin start the company in New York to build an egg-based biomanufacturing platform.
The Raptor platform is revealed alongside ~$11M in early financing and a multi-product biosimilar deal with a major pharma. Featured in The New York Times by Carl Zimmer.
Neion closes its Series A to scale the platform and expand a pipeline spanning biosimilars, medicines, reagents, and animal health.
The platform is called Raptor - a nod to the dinosaur ancestry of modern birds.
The CEO trained in aerospace at MIT and passed through GoogleX before biotech.
HQ sits at 1230 York Avenue, in the middle of New York's biomedical corridor.
Neion left stealth with a signed pharma partnership already in place.
Eggs have made vaccines for a century - Neion applies genetic engineering to make modern biologics.
The launch was covered in The New York Times by science writer Carl Zimmer.
Neion Bio does not currently publish a dedicated product-demo video channel. The links below point to the company's own media page and published interviews and coverage - the best available primary sources.
Neion Bio uses genetic engineering to turn chicken eggs into factories for complex biologic drugs, such as monoclonal antibodies, through its proprietary Raptor platform.
It was founded in 2024 by Demetrios (Dimi) Kellari, Co-Founder & CEO, and Dr. Sam Levin, Co-Founder & CTO, and is based in New York.
Roughly $11 million in early financing in March 2026, followed by an oversubscribed $23 million Series A in June 2026, both led by Caffeinated Capital.
Eggs are a naturally prolific system for producing complex, glycosylated proteins. Neion says the approach can lower capital costs up to 100x and cut manufacturing carbon footprint 10-100x versus conventional bioreactors.
Raptor is Neion's genetic-engineering platform that restricts recombinant protein production to the egg itself, enabling scalable, low-cost manufacturing of biologics and biosimilars.